FNDC3B and glioblastoma: In addition, we divided into the high-expression group (>1965.248214, n = 79) and the low-expression group (<1965.248214, n = 79) based on the median level of FNDC3B. The prognosis analysis showed that the expression of FNDC3B was interrelated to the survival rate in glioblastoma patients, and unoptimistic prognosis was observed in patients with high expression (Figure 5).